Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846143 · ClinicalTrials.gov registry record · Phase 1
Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01846143: Completed Phase 1 study, sponsored by Craig L Slingluff, Jr.
NCT01846143 is a Phase 1 study that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01846143, a Phase 1 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to learn what effects (good and bad) experimental phosphopeptide vaccines plus a tetanus peptide and other substances called polyICLC and Montanide ISA-51 have on people with melanoma. The investigators will also look at whether the experimental reagents cause any changes in the immune system.
Primary Outcome
Adverse events occurring in each subject will be reported until 30 days post administration of the last vaccine.
Interventions
- BIOLOGICAL pBCAR3-phosphopeptide
- BIOLOGICAL pIRS2-phosphopeptide
- BIOLOGICAL 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
What the finished NCT01846143 record still lists
NCT01846143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which pBCAR3-phosphopeptide is the first listed.
NCT01846143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01846143 about?
NCT01846143 is a clinical study titled "Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies". The purpose of this study is to learn what effects (good and bad) experimental phosphopeptide vaccines plus a tetanus peptide and other substances called polyICLC and Montanide ISA-51 have on people with melanoma. The investigators will also look at whether the experimental reagents cause any change...
What is the current status of trial NCT01846143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-05. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01846143?
The interventions under investigation include: pBCAR3-phosphopeptide (BIOLOGICAL), pIRS2-phosphopeptide (BIOLOGICAL), 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01846143?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01846143's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia